Bayer Bitterfeld decentralizes according to BetaCodex laws and adopts Cell Structure Design, as part of Bayer's DSO initiative

In a new LinkedIn article and news post, Andrea Heym, general manager at Bayer Bitterfeld, a 500-people unit producing pharmaceuticals such as Aspirin, reports on the successful Beta transformation of her company, as part of Bayer's global DSO initiative, which was initialized by Bayer CEO Bill Anderson, in 2024. The organizational development and decentralization work at Bayer Bitterfeld was accompanied by Silke Hermann and Niels Pflaeging (Red42), in close collaboration with the company's management and staff.

diagram-arrow-down

With the go-live of the consistently decentralized Cell Structure Design, the promise of Dynamic Shared Ownership (DSO) is coming true at Bayer Bitterfeld. In her article on LinkedIn, Andrea Heym says about the collaboration with Red42: “A huge thank you to Silke Hermann and Niels Pflaeging for their invaluable support in structuring the transformation process, in developing our new structure and most importantly changing the way we think about how we work together.”

Niels Pflaeging says about the case: “If Bitterfeld can achieve Beta transformation - why can't you? We, Silke Hermann and I, weren't allowed to talk about this case for quite a while time, and I am all the happier now that our wonderful client and OpenSpace Beta sponsor Andrea Heym is sharing the news! We can do it. Companies can become decentralized and democratic, everywhere, fast!”

Read Andrea Heym's original LinkedIn article from 26 January 2025 here

***

Learn more about the relationship between Bayer's DSO and Beta - according to Niels Pflaeging

Learn more about the Cell Structure Design approach, developed by Niels Pflaeging and Silke Hermann

Learn more about the Lean RFS approach by Ian Glenday, which was combined with Cell Structure Design to great effect, at Bayer Bitterfeld